AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00937274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T4 phage cocktail test
Description: T4 phages 106 PFU/ ml up to 5 days
Study NCT00937274 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Commercial T4 phage cocktail
Description: Treatment as recommended by the manufacturer (Microgen phages)
Study NCT00937274 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard oral rehydration solution (ORS)
Description: Standard hospital treatment with ORS
Study NCT02913183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: young Fresh Frozen Plasma
Description: Blood plasma from healthy male donors aged 18-30 years old.
Study NCT02913183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: old Fresh Frozen Plasma
Description: Blood plasma from healthy male donors aged 40-55 years old.
Study NCT02458144 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Total hip arthroplasty
Description: The minimally invasive anterior approach The patient is in supine position. The femoral neck is exposed in the interval between tensor fasciae latae, glutei medius and minimus muscles laterally, and sartorius and rectus femoris muscles medially. After osteotomy of the neck and extraction of the head the acetabulum is reamed to prepare for cup prosthesis. Following peritrochanteric capsulotomy the externally rotated, adducted and elevated femur is broached.~The MIS anterolateral approach The MIS anterolateral technique is a modified Watson-Jones Approach. The patient is in supine position. This approach uses the intermuscular plane between the gluteus medius and the tensor fascia latae. After the anterior capsule is excised, a disc of the femoral neck is removed.
Study NCT03495531 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Virtual Reality headset with calming scenery
Study NCT00725153 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Balafilcon A contact lenses (PureVision)
Description: Commercially marketed, soft contact lenses worn bilaterally for 10 hours
Study NCT00725153 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Etafilcon A contact lenses (Acuvue2)
Description: Commercially marketed, soft contact lenses worn bilaterally for 10 hours
Study NCT00618644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab 0.5 mg intravitreal injection
Study NCT04102267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine liposome injectable suspension
Description: Liposomal bupivacaine 266 mg via injection
Study NCT04313803 — intervention group
Intervention type: DEVICE
Intervention: CGM
Description: Dexcom CGM system
Study NCT03755453 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing aid: Phonak Audéo B90-Direct
Description: Hearing aids will be fitted to the participants individual hearing loss.
Study NCT04102267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine HCl without epinephrine via continuous infusion
Description: Bupivacaine HCl 300 mg via continuous infusion
Study NCT00212550 — intervention group
Intervention type: PROCEDURE
Intervention: Obtain standard three daily sputum samples vs. three samples on the first day for the diagnosis of pulmonary TB.
Description: Sputum induction
Study NCT03254745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist led pharmaceutical care
Description: The intervention in the study will be a pharmacist's intervention that will be provided to rheumatoid arthritis patients in order to improve their treatment outcomes. It will be in the form of a single (1) session by pharmacist (face-to-face) followed by written material for use at home. The pharmacist will look at the patient's baseline data and provide counseling. The venue for counseling will be the hospitals.
Study NCT03755453 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing aid: Phonak Audéo B90-Direct
Description: Hearing aids will be fitted to the participants individual hearing loss.
Study NCT03487250 — intervention group
Intervention type: DEVICE
Intervention: TenJet System
Description: Percutaneous ultrasound guided medial and lateral tenotomy using the TenJet HydroSurgery System
Study NCT03386123 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy for Insomnia
Description: Continuous maintenance of sleep diary, cognitive behaviour therapy, including cognitive restructuring, and behavioural change focusing on sleep restriction and safety behaviours.
Study NCT01677468 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intermediate embolization
Description: TACE with substasis using gelfoam
Study NCT01677468 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Complete embolization
Description: TACE with complete embolization using gelfoam
Study NCT00264719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide (Maxolon)
Description: Mothers will be given metoclopramide 10 mg 3 times a day for 7 days, 2 times a day from day 8 to 10 and once a day from 11th to 12th day
Study NCT00264719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 10 mg
Study NCT01414946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous nutrition with glucose and amino acids
Description: Glucose and amino acids intravenously starting 20 hours before the operation until the second postoperative day. Glucose provides 50% and amino acids 20% of each patient's measured resting energy expenditure.
Study NCT01414946 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous nutrition with amino acids
Description: Amino acids intravenously starting 20 hours before the operation until the second postoperative day. Amino acids providing 20% of each patient's measured resting energy expenditure.
Study NCT03386123 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Audiological Care
Description: Maintenance of sleep diary at key times. Psycho-education, provision of bedside sound generator.
Study NCT03386123 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sleep Support Group
Description: Maintenance of sleep diary at key times. Social support focused on tinnitus and sleep problems.
Study NCT06305572 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: QFR
Description: Patients suspected with CAD undergoing diagnostic coronary angiography with an indication for to perform invasive FFR were included. QFR was analyzed in an independent core laboratory (Uijeongbu Eulji Medical Center) using the software package QAngio XA 3D 2.1 (Medis Medical Imaging Systems, Leiden, the Netherlands).
Study NCT05323526 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Catquest-9SF questionnaire
Description: Patients complete the questionnaire preoperatively and postoperatively.
Study NCT05323526 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Demographics and clinical parameters
Description: The following clinical parameters are evaluated: age, gender, ocular and systemic comorbidities, educational level, preoperative and postoperative monocular distance uncorrected visual acuity (UVA), distance best spectacle-corrected visual acuity (BSCVA) of the eye for cataract surgery, binocular distance UVA and BSCVA, refraction, spherical equivalent (SE), and intraocular pressure.
Study NCT04537962 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Colgate Periogard® mouthwash
Description: Patients will be submitted to antisepsia of the oral mucosa with Colgate Periogard® mouthwash
Study NCT04537962 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Colgate Peroxyl® mouthwash
Description: Patients will be submitted to antisepsia of the oral mucosa with Colgate Peroxyl® mouthwash
Study NCT04537962 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Colgate Total® Mouthwash
Description: Patients will be submitted to antisepsia of the oral mucosa with Colgate Total® Mouthwash
Study NCT04537962 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Toothpaste with sodium monofluorophosphate
Description: Patients will be submitted to brushing with toothpaste with sodium monofluorophosphate
Study NCT04537962 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Toothpaste with sodium fluoride and zinc
Description: Patients will be submitted to brushing with toothpaste with sodium fluoride and zinc
Study NCT04537962 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Toothpaste with tin fluoride
Description: Patients will be submitted to brushing with toothpaste with tin fluoride
Study NCT04748744 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Butyrylcholinesterase
Description: Value of Butyrylcholinesterase as a Marker of Surgical Site Infection Following Surgery for Colorectal Diseases
Study NCT01694862 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Integrated FP/PNC service delivery
Description: The intervention uses a procedural tool building on existing MoH procedures. It has nine components: strengthening protocols, guidelines and training materials for integrated HIV-SRH care; training, mentorship; developing a mentoring and supervisory package; improving provider capacity; ensuring availability of minimum levels of equipment and supplies for integrated services; support supervision; organizational change (including reviewing use of available rooms) and role clarification; improving availability of IEC/BCC materials on FP and HIV; strengthening the referral system between FP and ART and the data collection and recording systems.
Study NCT03684629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the response of KPI and corresponding suggestion
Description: Standardized templates of medical record, evidence-based clinical pathway, and written care protocols are applied in all hospitals.The KPI of the AIS patients who were admitted to a single hospital continuously at the time of hospitalization were studied. Feedback system of performance measures: the hospital included in the study upload the medical records of all AIS patients by medical records scanning system since that month into the group. Quality control platform of Cerebral apoplexy in Zhejiang province extracts and analyze the data through the computer and calculates the corresponding monthly KPI. The hospitals will receive their own monthly KPI and the monthly highest KPI of all hospitals included in the study. Expert online consultation: based on the compare of the monthly KPI of all hospitals, Quality control platform will give corresponding suggestions to all hospitals for the improve of next month.
Study NCT01604330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen
Description: Baclofen will be administered orally for a maximum of 52 consecutive weeks. For the first 3 days, patients will receive baclofen in a dose of 5 milligrams three times a day; then the dose of baclofen will be increased to a maximum of 300 milligrams a day. In case of intolerance, dosage can be decreased.
Study NCT01604330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill will be administered orally for a maximum of 52 consecutive weeks. For the first 3 days, patients will receive sugar pill in a dose of 5 milligrams three times a day; then the dose of sugar pill will be increased to a maximum of 300 milligrams a day. In case of intolerance, dosage can be decreased.
Study NCT02266069 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Care Pathway for Primary Palliative Care
Description: Early identification of palliative care patients, anticipatory care planning, systematic symptom assessment, interdisciplinary collaboration, rigorous follow-up of the functional status of the patient and giving attention to the informal care givers.
Study NCT01913600 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Resolute Integrity Stent
Description: Drug eluting stent (DES)
Study NCT00793468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK598809
Description: GSK598809 once daily for 12 weeks
Study NCT04382781 — intervention group
Intervention type: DRUG
Intervention: NO-Immunosuppressive
Description: Patients not receiving immunosuppressive drugs
Study NCT04382781 — intervention group
Intervention type: DRUG
Intervention: Immunosuppressive
Description: Patients receiving immunosuppressive drugs (overall, and specific drugs)
Study NCT04382781 — intervention group
Intervention type: DRUG
Intervention: Immunoglubulins
Description: Patients receiving immunoglubulins
Study NCT04497480 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor-Assisted and Active Resistive Upper/Lower Extremities Rehabilitation Training System
Description: The Passive, Motor-Assisted and Active Resistive Upper/Lower Extremities Rehabilitation Training System is designed for patients conﬁned to bed at the long-term care facilities hospitals, in early rehabilitation. This system can induce a natural movements of the upper/lower limb with safe motorized passive movement, as well as motor-assisted and active resistive muscle training to stimulate nerves, increase blood circulation of aﬀected tissue, cell metabolism and improve joint mobility, in promoting upper/lower extremities motor recovery.
Study NCT01319097 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sorbion Sachet S
Description: Dressing is indicated for moderately to heavily exuding wounds.
Study NCT01892995 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ketamine
Study NCT01892995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Study NCT01892995 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Study NCT04283578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OT
Description: One group will receive OT for 4 weeks, then placebo or OT for 8 weeks
Study NCT04283578 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OT
Description: One group will receive OT for 4 weeks, then placebo or OT for 8 weeks
Study NCT04283578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo comparator
Description: One group will receive Placebo for 4 weeks, then Placebo or OT for 8 weeks.
Study NCT04283578 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: One group will receive Placebo for 4 weeks, then Placebo or OT for 8 weeks.
Study NCT04450498 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yuxi Walvax MPV ACYW® vaccine
Description: Walvax MPV ACYW vaccine is a sterile formulation of polysaccharide A,C,Y,W-135. One dose of 0.5 mL contains 50 µg of each A,C,Y,W-135 purified polysaccharide. The vaccine is presented in two vials: one containing the lyophilized cake of A,C,Y,W purified polysaccharides and the other the sterile water for injection as diluent. After reconstitution the one dose of 0.5 mL is ready for subcutaneous injection. The antigen content is similar to other internationally marketed polysaccharide vaccines that have been in use for decades as Menomune® Sanofi and Mencevax® Pfizer , all containing 50 µg of each A,C,Y,W purified polysaccharide that as one dose schedule are recommended for use in subjects > 2 years of age and have shown to be safe and immunogenic.
Study NCT00793468 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK598809
Description: GSK598809 once daily for 12 weeks
Study NCT00793468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Transdermal Patch
Description: All subjects will be treated during the 4 week open-label smoking cessation phase of the study. During Weeks 1-3, subjects will receive 21mg/day, and during Week 4, subjects will receive 14 mg/day. Those subjects who reached continuous abstinence on at least week 4 of the open-label phase will receive 7mg/day during Week 5 while taking GSK598809 or placebo.
Study NCT04450498 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sanofi Pasteur Menactra® vaccine
Description: The vaccine presentation is a full liquid formulation in a single dose of 0.5 mL with the following composition: Meningococcal group A polysaccharide 4 µg; Meningococcal group C polysaccharide 4 µg; Meningococcal group Y polysaccharide 4 µg; Meningococcal group W polysaccharide 4 µg; Diphtheria toxoid protein total 48 µg; Sodium phosphate 0.7 mg; Sodium chloride 4.35 mg.
Study NCT04550468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-Carb High-Fat breakfast
Description: Participants will receive 8 low-carb high-fat breakfast meal recipes to follow daily during 3 months.
Study NCT04550468 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low fat standard care control breakfast
Description: Participants will receive 8 low-fat breakfast meal recipes to follow daily during 3 months.
Study NCT00437086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PS-341
Description: 1.6 mg/m2 by IV; 4 out of 5 weeks
Study NCT00092456 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rotavirus vaccine, live, oral, pentavalent
Description: Three oral doses (\~8.81 X 10\^7 IU/Dose for Lot 1; \~8.01 X 10\^7 IU/Dose for Lot 2; and \~6.91 X 10\^7 IU/Dose for Lot 3) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination
Study NCT00092456 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching RotaTeq™ administered at 3 separate visits scheduled 4 to 10~weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination
Study NCT04218656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 Mg Oral Tablet
Description: 2.5 mg rivaroxaban twice a day in addition to Aspirin 100mg once a day (standard care).
Study NCT00158886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Topotecan will be provided as capsules for oral administration and will be administered at least 3 hours before radiation therapy.
Study NCT00158886 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: For radiation therapy, subjects will receive 180 centigray (cGy) per fraction to a total dose of 4500 cGy to the pelvis using a 3 or 4 field technique and high energy photons (>=6 megavolt \[mv\]).
Study NCT03466684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BIA-guided fluid resuscitation protocol
Description: In both groups, a multi-frequency BIA with eight tactile electrodes (Inbody S10 Biospace, Biospace Co. Ltd., Seoul, Korea) was used to assess body fluid status every 6h within the first 72h after admission to the ICU and daily for a period of 4 days.~BIA recording was not adjusted by clinicians in fluid restrict, pharmacological and mechanical means of therapy.~In contrast, in group BIA, fluid resuscitation protocol with adjustment determined according to HL measured by BIA.
Study NCT03466684 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional fluid resuscitation protocol
Description: Traditional fluid resuscitation strategy determined by treating clinicians according to usual clinical parameters.
Study NCT03693183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac/HPMC
Description: 0.30% Ketorolac/0.80%HPMC Ophthalmic solution administered 4 times per day for 2 days
Study NCT03693183 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HPMC
Description: 0.80% Hydroxypropyl Methylcellulose solution 4 times per day for 2 days
Study NCT03693183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle
Study NCT01707810 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piggyback method
Description: In the piggyback method IVC was not clamped in any case. Implantation method of the grafted IVC in recipient IVC was not standardized, being defined by the responsible surgeon during the procedure. In the two groups, all patients were submitted to simultaneous arterial and portal revascularization, according to the routine of the service.
Study NCT01707810 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: conventional method
Study NCT01735825 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: paclitaxel-coated balloon catheter with Iopromide coating
Description: Patients with coronary in-stent restenosis treated by drug eluting paclitaxel-coated balloon catheter
Study NCT01735825 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: drug eluting stent with everolimus
Description: Patients with coronary in-stent restenosis treated by drug eluting stent with everolimus
Study NCT01735825 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: seal-wing paclitaxel-eluting balloon catheter
Description: Patients with coronary in-stent restenosis treated by seal-wing paclitaxel-eluting balloon catheter
Study NCT00175149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfacalcidiol
Description: Alfacalcidiol are given to patientwith CKD 3-4 and secondary hyperparathyrodism. The PTH level is lowered to normal range. with increasing dose of alfacalcidiol and are followed for 6 month.
Study NCT01736644 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Electrocautery
Description: Use of electrocautery in tourniquet and tourniquetless total knee replacement surgery
Study NCT01736644 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar sealer Aquamantys
Description: Aquamantys use in tourniquet and tourniquetless total knee replacement.
Study NCT02648373 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: An educational video was watched based on Consumer Reports Choosing Wisely patient education supporting the recommendation that imaging is not helpful early for low back pain and the best strategy is to remain as active as possible. Key themes were discussed with a physical therapist and the patient's questions were answered.